Pharmaceutical composition comprising Cannabinoids
The present invention relates to a pharmaceutical composition comprising Δ9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resvertrol, and combinations thereof, wherein the composition exhibits an increased but negated psychoactivity with concurrent enhancement in therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.
1. A pharmaceutical composition comprising therapeutically effective amount of fully decarboxylated Δ9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule, in selected ratios by weight, wherein the at least small molecule is selected from the group consisting of Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), lecithin, one or more sugar(s), Resvertrol and combinations thereof; and
one or more ingredients selected from the group consisting of: Cayenne Pepper, Papaya Powder, vanilla, Cordyceps sinensis, Ganoderma lucidum, Pleurotis ostreatus or Hericeum Erinaceus , and combinations thereof.
2. The pharmaceutical composition of claim 1 , wherein a THC:CBD ratio ranges from 1:1 to 1:10 by weight.
3. The pharmaceutical composition of claim 2 , wherein the THC:CBD ratio ranges from 1:3 to 1:7 by weight.
4. The pharmaceutical composition of claim 1 , wherein a THC:small molecule ratio ranges from 10:1 to 1:10 by weight.
5. The pharmaceutical composition of claim 4 , wherein the THC:small molecule ratio ranges from 2:1 to 1:2 by weight.